Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced their upcoming webinar, "Model-Based Approach to Design Bispecific Modalities in Early Discovery" occurs Tuesday, February 4, 2020 at 2p.m. ET / 11a.m. PT.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced their fourth annual Quantitative Systems Pharmacology (QSP) Summit will occur May 20-21, 2020 at the MIT Samberg Conference Center in Cambridge, MA.
Helen Moore has been appointed Council at Society for Industrial and Applied Mathematics (SIAM).
Helen Moore, Director of Applied Mathematics at Applied BioMath, will use her position to proactively address challenges including decisions that need to be made about ethics issues, open access journal policies, declining journal subscriptions, and emerging platforms for communicating research results. Moore currently serves on SIAM's Council.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced their participation at The Society for Immunotherapy of Cancer (SITC) occurring November 6th-10th in National Harbor, Maryland. They will present two posters at the conference Friday, November 8th.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced their participation at PharmSci 360 occurring November 3-6, 2019 in San Antonio, Texas.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development,
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced they will host Quantitative Systems Pharmacology (QSP) Day November 12, 2019 from 2-7p.m. at the AC Hotel by Marriott San Francisco Airport/Oyster Point Waterfront in South San Francisco, CA.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, is proud to welcome Joshuaine Grant as Senior Principal Scientist.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced their participation in the following five sessions at ACoP10 occurring October 20-24, 2019 in Orlando, FL.
Monday, October 21st
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, is proud to welcome Kas Subramanian, PhD as Senior Director of Preclinical Modeling.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced their participation at the World Bispecific Summit occurring September 17-19, 2019 in Waltham, MA. John Burke, PhD, Co-Founder, President and CEO, Applied BioMath is chairing a session titled "Pioneering
In this interview with CEOCFO Magazine, Dr. John M. Burke, Co-founder, President and CEO of Applied BioMath discusses how Applied BioMath is focused on growing its team of industry leaders to better meet the needs of their biotech and pharma customers using mathematical modeling to de-risk and accelerate drug development. "Our growth plays a role in our brand recognition. Several of our most recent hires, including Alison Betts and Helen Moore, from Pfizer and AstraZeneca, respectively, are leaders in our industry," said Dr. John M.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced an agreement with Verseau Therapeutics for the delivery of systems pharmacology pharmacokinetic and target engagement analysis to provide early feasibility assessments for the treatment of cancer.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to accelerate and de-risk drug research and development, today announced their participation at the Immuno-Oncology Summit occurring August 5-9, 2019 in Boston, MA. John Burke, PhD, Co-Founder, President and CEO, Applied BioMath will present "Model Aided
Applied BioMath (www.appliedbiomath.com), the industry leader in applying systems and mechanistic modeling, simulation, and analysis to accelerate and de-risk drug research and development, is proud to welcome Alison Betts, as Senior Director of Scientific Collaborations and Fellow of Modeling & Simulation.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to accelerate and de-risk drug research and development (R&D), today announced their acceptance to present at the Alzheimer's Association International Conference® (AAIC) occurring July 14-18, 2019 in Los Angeles, CA. Lucia Wille, PhD, Associate Director of Biology at Applied BioMa
Applied BioMath (www.appliedbiomath.com), the industry leader in applying mechanistic modeling, simulation, and analysis to accelerate and de-risk drug research and development, is proud to welcome Helen Moore, PhD, as Director of Applied Mathematics. In this role, Dr.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to accelerate and de-risk drug research and development, today announced the speaker lineup for the Quantitative Systems Pharmacology (QSP) Summit occurring April 25-26, 2019 at Le Meridien Boston Cambridge in Cambridge, MA.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to accelerate and de-risk drug research and development, today announced their participation at the American Association for Cancer Research Annual Meeting occurring March 29 – April 3, 2019 in Atlanta, GA.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to accelerate and de-risk drug research and development, today announced their participation at the ICI-IO Combinations Summit occurring March 19-21, 2019 in Boston, MA.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to accelerate and de-risk drug research and development, today announced their participation at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) 2019 Annual Meeting occurring March 13-16, 2019 in Washington, D.C.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to accelerate and de-risk drug research and development, today announced the speaker for the QSP Industry & Academia Symposium occurring Thursday, February 28, 2019 from 5:45-8:00 p.m. at the Cambridge Innovation Center, 101 Main Street location, in Cambridge, MA.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to accelerate and de-risk drug research and development, today announced their Quantitative Systems Pharmacology (QSP) Summit will occur April 25-26, 2019 at Le Meridien Boston Cambridge in Cambridge, MA.
Applied BioMath, the industry-leader in applying mechanistic modeling, simulation, and analysis to accelerate and de-risk drug research and development, today announced a collaboration with Codiak BioSciences for the development and delivery of a semi-mechanistic pharmacokinetic, pharmacodynamic (SM-PK/PD) model for exo-STING, a precision-engineered exosome therapeutic targeting the pr
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced a collaboration with Obsidian Therapeutics to provide semi-mechanistic models and analysis services. Applied BioMath will create semi-mechanistic models, using in vitro and in vivo preclinical data, to aid in dose prediction and knowledge gap identification for Obsidian's promising therapeutic strategy. "Our Destablizing Domain platform is exceedingly powerful but also ph